Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. [electronic resource]
Producer: 20151217Description: 334-41 p. digitalISSN:- 1873-7560
- Administration, Oral
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal -- administration & dosage
- Benzamides -- administration & dosage
- Biomarkers, Tumor -- blood
- Delayed-Action Preparations
- Down-Regulation
- Humans
- Leuprolide -- administration & dosage
- Male
- Middle Aged
- Neoplasms, Hormone-Dependent -- blood
- Prospective Studies
- Prostatic Neoplasms -- blood
- Selective Estrogen Receptor Modulators -- administration & dosage
- Testosterone -- blood
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.